Patents by Inventor Xiaoyang Xia

Xiaoyang Xia has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Substituted macrocycles useful as kinases inhibitors and methods of use thereof
    Patent number: 10159663
    Abstract: The present invention is directed to novel substituted macrocycles compounds, pharmaceutically acceptable salts, solvates and hydrates thereof. The compounds and compositions of the present invention have protein kinases inhibitory activities and are expected to be useful for the treatment of protein kinases mediated diseases and conditions.
    Type: Grant
    Filed: August 18, 2015
    Date of Patent: December 25, 2018
    Assignee: Teligene Ltd.
    Inventors: Xiaoyang Xia, Dawei Zhang
  • HETEROCYLCIC COMPOUNDS AS IDH2 INHIBITORS
    Publication number: 20180134683
    Abstract: The present invention is directed to novel heterocyclic compounds, their derivatives, pharmaceutically acceptable salts, solvates and hydrates thereof. The compounds and compositions of the present invention have IDHs inhibitory activities and are useful for the treatment of Isocitrate dehydrogenases mediated diseases and conditions. Novel heterocyclic compounds disclosed herein include pyrimidines and triazines.
    Type: Application
    Filed: May 6, 2016
    Publication date: May 17, 2018
    Applicant: TELIGENE LTD.
    Inventors: Xiaoyang Xia, Dawei Zhang
  • SUBSTITUTED MACROCYCLES USEFUL AS KINASES INHIBITORS AND METHODS OF USE THEREOF
    Publication number: 20170216264
    Abstract: The present invention is directed to novel substituted macrocycles compounds, pharmaceutically acceptable salts, solvates and hydrates thereof. The compounds and compositions of the present invention have protein kinases inhibitory activities and are expected to be useful for the treatment of protein kinases mediated diseases and conditions.
    Type: Application
    Filed: August 18, 2015
    Publication date: August 3, 2017
    Applicant: TELIGENE LTD.
    Inventors: Xiaoyang Xia, Dawei Zhang
  • Glycine transporter-1 inhibitors
    Patent number: 9663476
    Abstract: The present invention provides compounds that are glycine transporter 1 (hereinafter referred to as GlyT-1) inhibitors and are therefore useful for the treatment of diseases treatable by inhibition of GlyT1 such as cognitive disorders associated with Schizophrenia, ADHD (attention deficit hyperactivity disorder), MCI (mild cognitive impairment), and the like. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
    Type: Grant
    Filed: April 29, 2014
    Date of Patent: May 30, 2017
    Assignee: AMGEN INC.
    Inventors: Stephen A. Hitchcock, Albert Amegadzie, Wenyuan Qian, Xiaoyang Xia, Scott S. Harried
  • Substituted aminoquinazolines useful as kinases inhibitors
    Patent number: 9388170
    Abstract: The present invention is directed to novel quinazolines, their derivatives, pharmaceutically acceptable salts, solvates and hydrates thereof. The compounds and compositions of the present invention have protein kinases inhibitory activities and are expected to be useful for the treatment of protein kinases mediated diseases and conditions.
    Type: Grant
    Filed: May 7, 2013
    Date of Patent: July 12, 2016
    Inventors: Xiaoyang Xia, Dawei Zhang
  • GLYCINE TRANSPORTER-1 INHIBITORS
    Publication number: 20150307457
    Abstract: The present invention provides compounds that are glycine transporter 1 (hereinafter referred to as GlyT-1) inhibitors and are therefore useful for the treatment of diseases treatable by inhibition of GlyT1 such as cognitive disorders associated with Schizophrenia, ADHD (attention deficit hyperactivity disorder), MCI (mild cognitive impairment), and the like. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
    Type: Application
    Filed: April 29, 2014
    Publication date: October 29, 2015
    Applicant: AMGEN INC.
    Inventors: Stephen A. Hitchcock, Albert Amegadzie, Wenyuan Qian, Xiaoyang Xia, Scott S. Harried
  • SUBSTITUTED AMINOQUINAZOLINES USEFUL AS KINASES INHIBITORS
    Publication number: 20150126539
    Abstract: The present invention is directed to novel quinazolines, their derivatives, pharmaceutically acceptable salts, solvates and hydrates thereof. The compounds and compositions of the present invention have protein kinases inhibitory activities and are expected to be useful for the treatment of protein kinases mediated diseases and conditions.
    Type: Application
    Filed: May 7, 2013
    Publication date: May 7, 2015
    Inventors: Xiaoyang Xia, Dawei Zhang
  • Glycine transporter-1 inhibitors
    Patent number: 8735383
    Abstract: The present invention provides compounds that are glycine transporter 1 (hereinafter referred to as GlyT-1) inhibitors and are therefore useful for the treatment of diseases treatable by inhibition of GlyT-1 such as cognitive disorders associated with Schizophrenia, ADHD (attention deficit hyperactivity disorder), MCI (mild cognitive impairment), and the like. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
    Type: Grant
    Filed: March 21, 2012
    Date of Patent: May 27, 2014
    Assignee: Amgen Inc.
    Inventors: Hitchcock Stephen, Albert Amegadzie, Wenyuan Qian, Xiaoyang Xia, Scott S. Harried
  • GLYCINE TRANSPORTER-1 INHIBITORS
    Publication number: 20120195985
    Abstract: The present invention provides compounds that are glycine transporter 1 (hereinafter referred to as GlyT-1) inhibitors and are therefore useful for the treatment of diseases treatable by inhibition of GlyT-1 such as cognitive disorders associated with Schizophrenia, ADHD (attention deficit hyperactivity disorder), MCI (mild cognitive impairment), and the like. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
    Type: Application
    Filed: March 21, 2012
    Publication date: August 2, 2012
    Applicant: Amgen Inc.
    Inventors: Stephen Hitchcock, Albert Amegadzie, Wenyuan Qian, Xiaoyang Xia, Scott S. Harried
  • Glycine transporter-1 inhibitors
    Patent number: 8183244
    Abstract: The present invention provides compounds that are glycine transporter 1 (hereinafter referred to as GlyT-1) inhibitors and are therefore useful for the treatment of diseases treatable by inhibition of GlyT1 such as cognitive disorders associated with Schizophrenia, ADHD (attention deficit hyperactivity disorder), MCI (mild cognitive impairment), and the like. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
    Type: Grant
    Filed: May 12, 2009
    Date of Patent: May 22, 2012
    Assignee: Amgen Inc.
    Inventors: Stephen Hitchcock, Albert Amegadzie, Wenyuan Qian, Xiaoyang Xia, Scott S. Harried
  • GLYCINE TRANSPORTER-1 INHIBITORS
    Publication number: 20090227595
    Abstract: The present invention provides compounds that are glycine transporter 1 (hereinafter referred to as GlyT-1) inhibitors and are therefore useful for the treatment of diseases treatable by inhibition of GlyT1 such as cognitive disorders associated with Schizophrenia, ADHD (attention deficit hyperactivity disorder), MCI (mild cognitive impairment), and the like. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
    Type: Application
    Filed: May 12, 2009
    Publication date: September 10, 2009
    Inventors: Stephen Hitchcock, Albert Amegadzie, Wenyuan Qian, Xiaoyang Xia, Scott S. Harried
  • Glycine transporter-1 inhibitors
    Patent number: 7538114
    Abstract: The present invention provides compounds that are glycine transporter 1 (hereinafter referred to as GlyT-1) inhibitors and are therefore useful for the treatment of diseases treatable by inhibition of GlyT1 such as cognitive disorders associated with Schizophrenia, ADHD (attention deficit hyperactivity disorder), MCI (mild cognitive impairment), and the like. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
    Type: Grant
    Filed: June 26, 2007
    Date of Patent: May 26, 2009
    Assignee: Amgen Inc.
    Inventors: Stephen Hitchcock, Albert Amegadzie, Wenyuan Qian, Xiaoyang Xia, Scott S. Harried
  • Glycine transporter-1 inhibitors
    Publication number: 20080004289
    Abstract: The present invention provides compounds that are glycine transporter 1 (hereinafter referred to as GlyT-1) inhibitors and are therefore useful for the treatment of diseases treatable by inhibition of GlyT1 such as cognitive disorders associated with Schizophrenia, ADHD (attention deficit hyperactivity disorder), MCI (mild cognitive impairment), and the like. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
    Type: Application
    Filed: June 26, 2007
    Publication date: January 3, 2008
    Inventors: Stephen Hitchcock, Albert Amegadzie, Wenyuan Qian, Xiaoyang Xia, Scott Harried